Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laboratory measurement of direct oral anticoagulants in atrial fibrillation
2016-002105-18Phase 4Terminated
- Sponsor
- Haartman Hospital
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dabigatran, rivaroxaban, apixaban and edoxaban in Atrial fibrillation (AFib), sponsored by Haartman Hospital. Primary endpoints: Effect of DOACs on routine coagulation assays and Effect of DOACs on specialized coagulation assays. Started Oct 2016; status: terminated.
02
Drugs
dabigatranrivaroxabanapixabanedoxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2016-002105-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002105-18.